Summary
Cigna Group's (CI) third quarter 2023 results show a year-over-year decrease in Shareholders' Net Income, largely due to the absence of a significant gain from asset divestitures in the prior year. However, on an adjusted basis, the company demonstrated resilience, with Adjusted Income from Operations showing an increase for the quarter, driven by solid performance in its Evernorth Health Services and Cigna Healthcare segments. Total revenues saw a healthy increase, propelled by growth in Pharmacy revenues and Premiums, alongside a notable rise in Fees and other revenues, indicating strong top-line expansion. Operational highlights include a significant increase in medical customers, reflecting successful growth strategies. The company's liquidity remains robust, supported by substantial cash and investment reserves, and available credit facilities. While facing headwinds from increased medical costs and selling, general, and administrative expenses, Cigna Group's strategic investments in technology and care solutions appear to be laying the groundwork for future growth. Investors should monitor the ongoing litigation and regulatory matters, particularly the Medicare Advantage risk adjustment investigations, which, despite recent settlements, carry inherent uncertainties.
Financial Highlights
48 data points| Revenue | $49.05B |
| Cost of Revenue | $33.64B |
| Gross Profit | $15.41B |
| SG&A Expenses | $3.79B |
| Operating Income | $2.24B |
| Interest Expense | $353.00M |
| Net Income | $1.41B |
| EPS (Basic) | $4.79 |
| EPS (Diluted) | $4.74 |
| Shares Outstanding (Diluted) | 297.13M |
Key Highlights
- 1Shareholders' Net Income decreased by 49% year-over-year to $1.41 billion, primarily impacted by the absence of a gain from the sale of international businesses in the prior year.
- 2Adjusted Income from Operations increased by 8% to $2.01 billion for the quarter, indicating underlying business strength, though it decreased by 6% year-to-date due to divestitures.
- 3Total revenues grew by 8% to $49.05 billion for the quarter, driven by a 5% increase in Pharmacy revenues, a 15% increase in Premiums, and a 17% increase in Fees and other revenues.
- 4Medical customers increased by 9% to 19.6 million, showing strong customer acquisition and retention, particularly in U.S. Commercial and Medicare Advantage segments.
- 5The company's liquidity remains strong, with $8.7 billion in cash and short-term investments and $5.0 billion in undrawn committed capacity under its revolving credit agreements as of September 30, 2023.
- 6Selling, general, and administrative expenses increased by 20% for the quarter, driven by growth-related investments and litigation settlement charges.
- 7Cigna Group settled a Medicare Advantage risk adjustment investigation for approximately $135 million plus interest, and also entered into a Corporate Integrity Agreement.